A new trading day began on Monday, with Intellia Therapeutics Inc (NASDAQ: NTLA) stock price down -3.10% from the previous day of trading, before settling in for the closing price of $24.52. NTLA’s price has ranged from $5.90 to $26.99 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -20.04%. Meanwhile, its annual earnings per share averaged 21.08%. With a float of $101.56 million, this company’s outstanding shares have now reached $105.33 million.
Intellia Therapeutics Inc (NTLA) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Intellia Therapeutics Inc is 5.39%, while institutional ownership is 87.75%. The most recent insider transaction that took place on Oct 01 ’25, was worth 539. In this transaction EVP, Chief Scientific Officer of this company sold 31 shares at a rate of $17.38, taking the stock ownership to the 105,184 shares. Before that another transaction happened on Oct 01 ’25, when Company’s VP, Chief Accounting Officer sold 1,871 for $17.38, making the entire transaction worth $32,518. This insider now owns 55,266 shares in total.
Intellia Therapeutics Inc (NTLA) Earnings and Forecasts
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -1.34 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.98 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.08% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 31.91% during the next five years compared to -20.04% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Here are Intellia Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.19. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 48.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.69, a number that is poised to hit -1.01 in the next quarter and is forecasted to reach -3.85 in one year’s time.
